Hikma Pharm Rg
HIK
GBP
STOCK MARKET:
LSS
Open
 
...
Large gap with delayed quotes
Last quote
01/20/2026 - 13:54:14
Bid
01/20/2026 - 14:01:51
Bid
Volume
Ask
01/20/2026 - 14:01:51
Ask
Volume
15.3200
-0.11 ( -0.71% )
15.3100
473
15.3300
828
More information
Analysis by TheScreener
16.01.2026
Evaluation Slightly positive  
Interest Weak  
Sensibility Low  
Analysis date: 16.01.2026
Global Evaluation
  Slightly positive
The stock is classified in the slightly positive zone since 11.11.2025.
Interest
  Weak
Two stars since 16.01.2026.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 16.01.2026 at a price of 1570.00.
Evaluation
  Strongly undervalued
 
Based on its growth potential and our own criteria, we believe the share price is currently undervalued.
MT Tech Trend
  Neutral
 
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 07.11.2025.
4wk Rel Perf
  -1.78%
 
The four-week dividend-adjusted underperformance versus STOXX600 is 1.78%.
Sensibility
  Low
Low, no change over 1 year.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -0.02%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 2.36%.
Mkt Cap in $bn
  4.61
With a market capitalization between $2 & $8bn, HIKMA PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
  1.58
A "Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings" ratio higher than 1.5 indicates that the stock's price presents a discount to growth >40% in this case.
LT P/E
  8
The estimated PE is for the year 2027.
LT Growth
  8.47%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  8
Over the last seven weeks, an average of 8 analysts provided earnings per share estimates.
Dividend Yield
  4.19%
The twelve month estimated dividend yield represents 33.46% of earnings forecasts.
Beta
  58
For 1% of index variation, the stock varies on average by 0.58%.
Correlation
  0.33
Stock movements are strongly independent of index variations.
Value at Risk
  124.81
The value at risk is estimated at GBp 124.81. The risk is therefore 7.95%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  11.10.2006